Table 2. Steady-state pharmacokinetic parameters for apixaban, rivaroxaban, and edoxaban.

	Apixaban		Rivaroxaban		Edoxaban	
Dosage (ng/mL)	2.5 mg BID	5 mg BID	10 mg QD	15 mg QD	30 mg QD	60 mg QD
C_{max} (ng/mL)	156.4 ± 40.4	256.4 ± 56.7*	202.3 ± 91.8	248.0 ± 111.7	119.2 ± 35.1*$^{+}$	196.0 ± 48.6$^{\#}$
C_{min} (ng/mL)	73.8 ± 30.6	101.6 ± 41.7*	27.6 ± 20.2*$^{\times}$	27.7 ± 12.8*$^{\times}$	27.4 ± 16.1*$^{\times}$	27.2 ± 17.8*$^{\times}$
AUC (ng.h/mL)	2,920 ± 960	4,550 ± 1,210*	2,090 ± 550$^{\times}$	2,710 ± 590$^{\times+}$	940 ± 220$^{\times}$	1,290 ± 200*$^{\times}$
T_{max} (h)	3.26 ± 0.14	3.13 ± 0.21	3.40 ± 0.47	3.38 ± 0.59	1.66 ± 0.13*$^{\times+\S}$	1.60 ± 0.14*$^{\times+\S}$
$T_{1/2}$ (h)	5.81 ± 1.56	4.65 ± 1.20	6.78 ± 1.56	6.35 ± 1.55	13.42 ± 9.21*$^{\times+\S}$	10.4 ± 9.43*$^{\times+\S}$

Notes:

QD, once daily; BID, twice daily; C_{max}, peak plasma concentration; C_{min} concentration at 12 h post-dose for BID and 24 h post-dose for QD; AUC, area under the plasma concentration–time curve across 1 d; T_{max}, time to peak plasma concentration; $T_{1/2}$, half-life.

PK parameters for BID calculated from 0 to 12-h data.

Data are presented as the mean and standard deviation.

*$p < 0.001$ vs. 2.5 mg BID apixaban, $^{+}p < 0.01$ vs. 10 mg QD rivaroxaban, $^{\#}p < 0.001$ vs. 30 mg QD edoxaban, $^{\times}p < 0.001$ vs. 5 mg BID apixaban, $^{\S}p < 0.001$ vs. 15 mg QD rivaroxaban.